381. Plasma C4d levels correlate with treatment response and renal activity in proliferative lupus nephritis.
作者: Agneta Zickert.;Caroline Grönwall.;Anna Juto.;Lina-Marcela Diaz-Gallo.;Sepehr Sarrafzadeh Zargar.;Ann Mongan.;Henk-Andre Kroon.;Myriam Martin.;Anna M Blom.;Edmund Chang.;Iva Gunnarsson.
来源: Rheumatology (Oxford). 2025年64卷8期4825-4833页
The investigation of complement factors in lupus nephritis (LN) in relation to treatment response and the impact of underlying genetics of C4.
382. What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?
作者: Fernando Zanghelini.;Georgios Xydopoulos.;Stephanie Howard Wilsher.;Oyewumi Afolabi.;Dale Webb.;Joe Eddison.;Thomas A Ingram.;Clare Clark.;Jill Hamilton.;Raj Sengupta.;Karl Gaffney.;Richard Fordham.
来源: Rheumatology (Oxford). 2025年64卷9期4913-4920页
The objective of this study was to develop an economic model to determine the annual cost of delayed axial SpA diagnosis in the UK, adopting both National Health Service (NHS) and societal perspectives.
383. Incidence and prevalence of Behçet's disease in Oslo, Norway: a two-decade population-based analysis.
作者: Jing Lisa Li Lorentsen.;Cathrine Brunborg.;Anders T Aasebø.;Jørgen Valeur.;Espen A Haavardsholm.;Øyvind Molberg.;Øyvind Palm.;Karoline Lerang.
来源: Rheumatology (Oxford). 2025年64卷8期4703-4712页
To estimate the incidence and prevalence of Behçet's disease (BD) in Oslo, Norway from 1999 to 2021.
384. Social and healthcare professionals' work to establish coherent rehabilitation pathways for people with inflammatory arthritis: a qualitative study.
作者: Helle Feddersen.;Camilla Vestergaard Aarøe.;Jens Søndergaard.;Lena Andersen.;Bettina Munksgaard.;Jette Primdahl.
来源: BMC Rheumatol. 2025年9卷1期48页
Professionals in health and social care are challenged by the complexity and fragmentation across primary and secondary levels of care. To study coherent rehabilitation pathways, we focused on people with inflammatory arthritis admitted to a specialised rehabilitation stay as these pathways will involve a myriad of different professionals from primary and secondary levels of care. This study aimed to explore how health and social care professionals establish coherent rehabilitation pathways for people with inflammatory arthritis across primary and secondary levels of care and how organisational factors influence on workflow.
385. Real-world care patterns and specialist encounters of patients with systemic autoimmune rheumatic disease-related interstitial lung disease in the United States: a retrospective administrative claims database analysis.
作者: Joseph Yang.;Michael A Head.;Kevin D Schott.;Hiangkiat Tan.;Rachel Djaraher.;Christopher L Crowe.;Mark Napier.;Kenneth Kossack.;Amy L Olson.;Elana J Bernstein.
来源: Rheumatology (Oxford). 2025年64卷8期4713-4721页
We aimed to describe the demographics, clinical characteristics and care patterns of patients with systemic autoimmune rheumatic diseases (SARD) prior to their interstitial lung disease (ILD) diagnosis.
386. Arterial cardiovascular outcomes and venous thromboembolism in patients with primary Sjögren's syndrome: a Danish cohort study.
作者: Pierre Loiseau.;Aurélie Mailhac.;Pierre Duhaut.;Reimar W Thomsen.
来源: Rheumatology (Oxford). 2025年64卷8期4678-4686页
To evaluate whether atherosclerotic cardiovascular disease outcomes, venous thromboembolism, heart failure, and cardiovascular mortality are elevated in patients with primary Sjögren's syndrome (pSS) compared with a matched cohort from the general population.
387. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index exhibits an L-shaped association with all-cause mortality in rheumatoid arthritis patients: a retrospective cohort study.
作者: Jialin Zhang.;Yanhua Lin.;Jingyan Zeng.;Guihu Luo.;Pan Liao.;Qianyun Chen.;Han Zhong.;Simei Liang.;Cailiu Zhou.;Bin Yang.;Xing Li.
来源: BMC Rheumatol. 2025年9卷1期47页
The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel biomarker reflecting inflammation, nutrition, and immune status, and its potential clinical significance and prognostic role in patients with rheumatoid arthritis (RA) has not been reported.
389. Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Rasch measurement theory to identify items and domains.
作者: Tim Pickles.;Mike Horton.;Karl Bang Christensen.;Rhiannon Phillips.;David Gillespie.;Neil Mo.;Janice Davies.;Susan Campbell.;Ernest Choy.
来源: Rheumatology (Oxford). 2025年64卷9期4902-4912页
Disease activity (DA) monitoring is a standard of care in RA. There is demand for achieving this through patient-reported outcome measures (PROMs). The aim of this study was to determine which items could be used to measure the construct of RA DA, by analysing legacy PROMs, using Rasch measurement theory (RMT) analyses.
390. MRI patterns of thigh muscle involvement in immune-mediated necrotizing myopathy and dermatomyositis.
作者: Anson W Wilks.;Kiana M Vakil-Gilani.;William D Rooney.;Dongseok Choi.;Daniela Ghetie.;Nizar Chahin.
来源: BMC Rheumatol. 2025年9卷1期46页
Immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) are characterized by weakness, hyperCKemia, associated autoantibodies, and varying extramuscular manifestations. Muscle MRI, currently subordinate to histopathology and serology in idiopathic inflammatory myopathy (IIM) classification, has an evolving role. Our study aims to define thigh muscle MRI involvement in IMNM and DM by direct comparison.
391. Transitional and CD21- PD-1+ B cells are associated with remission in early rheumatoid arthritis.
作者: Sarah McGrath.;Boel Sundbeck.;Katrin Thorarinsdottir.;Charlotte A Jonsson.;Alessandro Camponeschi.;Monica Leu Agelii.;Anna-Karin H Ekwall.;Merete Lund Hetland.;Mikkel Østergaard.;Till Uhlig.;Michael Nurmohamed.;Jon Lampa.;Dan Nordström.;Kim Hørslev-Petersen.;Bjorn Gudbjornsson.;Gerdur Gröndal.;Ronald van Vollenhoven.;Anna Rudin.;Inga-Lill Mårtensson.;Inger Gjertsson.
来源: BMC Rheumatol. 2025年9卷1期45页
Early initiation of effective treatment is associated with positive long-term prognosis for patients with rheumatoid arthritis (RA). Currently, there are no biomarkers in clinical use to predict treatment response. A predictor of treatment response may be the B-cell compartment, as this is altered in RA patients, making it a potential candidate for predicting treatment response. In this study, we sought to identify B-cell subset(s) at diagnosis that might be associated with Clinical Disease Activity Index (CDAI) remission at 24-week follow-up.
393. Prevalence and factors associated with fatigue in patients with psoriatic arthritis: a systematic review and meta-analysis.
Fatigue is a prominent symptom in patients with psoriatic arthritis (PsA). There was a wide variety of statistics previously reported on fatigue prevalence in patients. This systematic review examined the current literature to derive the overall prevalence of fatigue and risk factors in PsA patients.
394. Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab.
作者: Roberto Depascale.;Raffaele Da Mutten.;Julius Lindblom.;Nursen Cetrez.;Leonardo Palazzo.;Luca Iaccarino.;Andrea Doria.;Dionysis Nikolopoulos.;Mariele Gatto.;Ioannis Parodis.
来源: Rheumatology (Oxford). 2025年64卷8期4650-4658页
To determine SLE endotypes according to B cell immunophenotyping and serological profile and assess endotypes' response to belimumab.
395. Analysis of foot function in terms of different pharmacological treatments in a cohort of patients with rheumatoid arthritis: a longitudinal study.
作者: Maria Gamez-Guijarro.;Andres Reinoso-Cobo.;Manuel Pardo-Rios.;Ana-Belen Ortega-Avila.;Laura Ramos-Petersen.;Gabriel Gijon-Nogueron.;Eva Lopezosa-Reca.
来源: BMC Rheumatol. 2025年9卷1期43页
This study examines the influence of pharmacological treatments on foot functionality in patients with rheumatoid arthritis over a five-year period. A longitudinal analysis categorized patients into different treatment groups, assessing their foot function using the Foot Function Index (FFI) at the start and end of the study. The groups are based on their pharmacological treatment. Pharmacological treatment groups were categorized into: I methotrexate (MTX), II MTX plus biological treatments (including all variables), III biological treatment alone, and IV a miscellaneous group comprising patients with diverse treatments, including patients for whom various drugs had failed or who had not achieved remission with pharmacological treatment. The study included 206 RA patients with an average age of 58.32 years and a disease evolution of 15.28 years. The analysis of the FFI in total and across its domains of pain, disability, and activity revealed significant differences only in the pain domain (p = 0.011), with a trend toward worsening over time observed in the other domains. Notably, MTX treatment showed improvement in the pain domain (decreasing from 45.76 in 2018 to 40.43 in 2023). Findings suggest that while pharmacological treatments are essential in managing rheumatoid arthritis, their impact on foot function is limited, with MTX demonstrating the most significant benefit in terms of pain reduction.
396. Anti-β2glycoprotein I-induced neutrophil extracellular traps cause endothelial activation.
作者: Silvia Mancuso.;Mattia Caliste.;Andrea Petretto.;Elisa Corsiero.;Nicole Grinovero.;Antonella Capozzi.;Gloria Riitano.;Cristiana Barbati.;Simona Truglia.;Cristiano Alessandri.;Maurizio Sorice.;Michele Bombardieri.;Fabrizio Conti.
来源: Rheumatology (Oxford). 2025年64卷8期4796-4805页
Neutrophil extracellular traps (NETs) involvement in antiphospholipid syndrome (APS) pathogenesis is known, but the role of anti-β2glycoprotein I (aβ2GPI) antibodies-induced NETs in triggering a procoagulant and proinflammatory phenotype in endothelial cells (ECs) remains to be evaluated. This study investigated whether NET-aβ2GPI can activate ECs and whether NET-aβ2GPI and NET-phorbol myristate acetate (PMA) have different proteomic profiles.
397. IgA vasculitis associated with chronic myelomonocytic leukemia.
作者: Bénédicte Rouvière.;Francois Chasset.;Noémie Abisror.;Pierre Hirsch.;Olivier Fain.;Arsène Mékinian.; .
来源: BMC Rheumatol. 2025年9卷1期42页
IgA vasculitis is a predominantly pediatric autoimmune disease characterized by IgA deposit in small vessels. Chronic myelomonocytic leukemia (CMML) is a rare hematological malignancy classified within myelodysplastic syndromes. Here, we present a previously unrecognized case of CMML associated with IgA vasculitis. A 62-year-old woman presented with necrotic and infiltrated purpura and mild arthralgia, primarily affecting the knees and wrists, without gastrointestinal or kidney involvement. A comprehensive screening for other etiologies was unremarkable. Blood tests showed an increase of monocyte count and circulating monocyte phenotyping was consistent with CMML. Bone marrow analysis showed no blast cells or karyotypic abnormalities. Genetic testing identified an NRAS mutation. Autoantibody screening and viral serologies were negative. A skin biopsy revealed small-vessel vasculitis with IgA immune deposits. CMML can be associated with autoimmune diseases, such as polyarteritis nodosa and cutaneous leukocytoclastic vasculitis. However, this is the first report of IgA vasculitis occurring in the context of low risk CMML.
398. Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics.
作者: Jasvinder A Singh.;Larry R Hearld.;Seth Eisen.;W Winn Chatham.;Sonali Narain.;Narender Annapureddy.;Diane L Kamen.;Kimberly Trotter.;Vikas Majithia.;Cathy Lee Ching.;Zineb Aouhab.;Swamy Venuturupalli.;Daniel J Wallace.;Rosalind Ramsey-Goldman.;Alfred Kim.;Maureen McMahon.;S Sam Lim.;Kalpana Bhairavarasu.;Alexa Meara.;Kenneth Kalunian.;T Mark Beasley.; .
来源: Rheumatology (Oxford). 2025年64卷8期4631-4640页
The objective of this study was to examine the clinical outcomes during the implementation of a self-administered patient decision-aid (PtDA) for lupus.
400. Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis.
作者: Ali Y Ayla.;Naveen R Kalavar.;Mark Pimentel.;Walter Morales.;Laura K Hummers.;Ami A Shah.;Michael Hughes.;Zsuzsanna H McMahan.
来源: Rheumatology (Oxford). 2025年64卷10期5230-5237页
Functional antibodies play a role in SSc gastrointestinal (GI) disease, but their clinical relevance is unclear. We examined GI and extraintestinal features associated with anti-muscarinic-3 receptor (M3R) antibodies in SSc patients.
|